Core Viewpoint - Haosen Pharmaceutical reported a revenue of 359 million yuan for the first three quarters of 2025, marking a year-on-year growth of 12.13%, and a net profit attributable to shareholders of 88 million yuan, with a growth of 1.45% [1] Financial Performance - The total assets of Haosen Pharmaceutical reached 1.569 billion yuan, reflecting a year-on-year increase of 5.55% [1] - Revenue growth of 12.13% and net profit growth of 1.45% indicate stable financial performance despite market challenges [1] Innovation and R&D - The company prioritizes technological innovation and has established a strong mechanism for innovation through collaborations with universities and research institutions [1] - Haosen Pharmaceutical holds 25 authorized patents, with 23 being invention patents, covering key preparation processes and equipment [1] - The collaboration with Hangzhou Haosen Drug Research Institute has enhanced R&D efficiency and market responsiveness [1] Market Expansion - The company is actively expanding into high-end markets in the Americas and Europe, enhancing brand influence through participation in international exhibitions [1] - Establishing long-term partnerships with leading global clients like TEVA has strengthened its position in the global pharmaceutical supply chain [1] Industry Outlook - Haosen Pharmaceutical anticipates continued growth in the emerging pharmaceutical sector, viewing the bulk procurement of chemical drugs as an opportunity for raw material pharmaceutical companies [1]
延续稳健成长势头 海森药业前三季度营收同比增长12.13%升至3.59亿元